Login / Signup

A glycolytic metabolite that drives BRCA2 haploinsufficiency.

Peng Jiang
Published in: Cell (2024)
Many types of tumor cells alter metabolic pathways to meet their energy and biosynthetic demands for proliferation or stress adaptation. In this issue of Cell, Kong et al. find that the glycolytic metabolite methylglyoxal causes cancer-associated mutant single-base substitution features by inducing BRCA2 proteolysis, leading to functional haploinsufficiency of BRCA2.
Keyphrases
  • breast cancer risk
  • single cell
  • signaling pathway
  • cell therapy
  • stem cells
  • mesenchymal stem cells
  • heat stress
  • wild type